Shares of Heron Therapeutics Inc.
HRTX,
-4.02%
gained 3.0% in trading on Thursday after the company said the Food and Drug Administration had approved its non-opioid anesthetic for use in some surgical patients. The drug, Zynrelef, is expected to become available to hospitals in July. Heron's stock is down 16.2% for the year, while the S&P 500
SPX,
+1.05%
is up 8.1%.